KDIGO 2026 CKD Guidelines: Key Updates for Nephrology Practice

Overview of the 2026 KDIGO CKD Guideline Updates

If you manage patients with chronic kidney disease — and in primary care, internal medicine, and endocrinology, that describes a growing share of your panel — the 2026 KDIGO update is one you need to read carefully. These are not incremental tweaks. The guidelines fundamentally expand which patients should receive renoprotective pharmacotherapy, introduce an entirely new drug class to CKD management, and revise how clinicians should think about disease staging and progression risk.

The Kidney Disease: Improving Global Outcomes (KDIGO) organization released updated clinical practice guidelines for chronic kidney disease management in early 2026. These guidelines represent the most significant revision to CKD management recommendations in several years, incorporating new evidence from landmark trials including FLOW, EMPA-KIDNEY, and DAPA-CKD. For related updates on diabetic kidney disease and nonsteroidal MRAs, see our dedicated review.

What follows is a practical breakdown of the three most consequential changes and what they mean for the prescribing decisions you face in clinic.

SGLT2 Inhibitor Recommendations Expanded

The updated guidelines now recommend SGLT2 inhibitors for all patients with CKD and eGFR 20-45, regardless of diabetes status. This represents a significant expansion from the 2024 guidelines which limited the recommendation to eGFR above 25.

Why This Matters at the Bedside

The practical impact of this change is substantial. Under the prior guidelines, a patient with an eGFR of 22 and no diabetes did not meet criteria for SGLT2 inhibitor initiation — even though the mechanism of renal benefit is hemodynamic and independent of glucose control. That gap between evidence and recommendation left many clinicians in a difficult position, particularly when managing patients with progressive CKD who had limited pharmacologic options for slowing decline. The 2026 revision closes that gap by recognizing that the renoprotective effects of SGLT2 inhibitors operate through tubuloglomerular feedback modulation and reduced intraglomerular pressure, neither of which depends on baseline glycemic status.

For the clinician starting these agents in patients with eGFR in the 20-25 range, the expected initial dip in eGFR of 3-5 mL/min remains a point of patient concern. This dip is hemodynamic, not nephrotoxic, and reflects the intended reduction in hyperfiltration. It should not prompt discontinuation. Counsel patients that this early decline is a sign the drug is working as intended, and plan a follow-up creatinine check at 2-4 weeks to confirm stabilization.

Practical Initiation and Monitoring

Both dapagliflozin 10 mg and empagliflozin 10 mg are appropriate choices with no dose titration required. Check a baseline metabolic panel and repeat at 2-4 weeks. Watch for volume depletion in patients on concurrent diuretics — this is the most common reason clinicians hesitate with SGLT2 inhibitor initiation, and in most cases a modest diuretic dose reduction at the time of SGLT2 inhibitor start is sufficient to prevent symptomatic hypotension. Monitor for ketoacidosis risk in patients with type 1 diabetes or those on very low carbohydrate diets, though this population falls outside the typical CKD indication.

GLP-1 Receptor Agonists Enter CKD Guidelines

For the first time, GLP-1 receptor agonists are included in CKD management guidelines based on the FLOW trial data showing semaglutide reduced the primary kidney composite endpoint by 24%.

What This Changes for Your CKD Patients

Until the FLOW trial results, GLP-1 receptor agonists were prescribed to CKD patients primarily for their diabetes and cardiovascular indications, with any renal benefit considered secondary. The 2026 KDIGO update formally recognizes kidney protection as a primary reason to prescribe these agents. This is a meaningful shift: it means the patient with type 2 diabetes, CKD stage 3b, and well-controlled A1c who might not otherwise need intensification of glucose-lowering therapy now has a kidney-specific indication for semaglutide.

The clinical question most physicians will face is how to layer GLP-1 agonists alongside SGLT2 inhibitors. The guidelines do not mandate a specific sequencing, but the evidence supports starting both when indicated. SGLT2 inhibitors have the strongest renal evidence base and the simplest initiation (once-daily oral, no titration). GLP-1 agonists require subcutaneous injection for most formulations and a titration period to manage gastrointestinal side effects. A reasonable approach for most patients is to establish the SGLT2 inhibitor first, confirm tolerability, and then add the GLP-1 agonist as a second renoprotective agent.

Addressing Common Concerns

Gastrointestinal tolerability remains the primary barrier to GLP-1 agonist uptake. Nausea affects a significant proportion of patients during the titration phase and is the most common reason for discontinuation. Starting at the lowest available dose and titrating slowly over 4-8 weeks minimizes this. Patients should be advised that nausea typically diminishes after the first few weeks and that taking the injection on a consistent day each week helps establish tolerance. For patients who cannot tolerate subcutaneous semaglutide, oral semaglutide is an alternative, though absorption requirements (taken on an empty stomach with minimal water, 30 minutes before food) add complexity.